Last updated: September 3, 2026
Bepridil hydrochloride is a mature, low-revenue cardiovascular drug with limited geographic availability and no meaningful branded growth platform. Its commercial history is defined by U.S. withdrawal, generic competition, safety-related prescribing constraints, and continued niche use in Japan for angina and selected atrial arrhythmias. Public sources do not identify material standalone revenue for bepridil hydrochloride, and the product has no current global blockbuster exposure.
What is bepridil hydrochloride used for?
Bepridil hydrochloride is a diphenylalkylamine calcium-channel blocker with additional sodium- and potassium-channel activity. It was developed for chronic stable angina and has also been used in Japan for atrial fibrillation and atrial flutter, particularly when other antiarrhythmic options are inadequate [1, 2].
Its electrophysiologic activity creates a commercial tradeoff:
- It can suppress abnormal atrial electrical activity.
- It can prolong the QT interval.
- It can cause torsades de pointes and other serious ventricular arrhythmias.
- It requires more restrictive patient selection and monitoring than many competing cardiovascular drugs.
The product is therefore a specialty or niche therapy rather than a broad primary-care cardiovascular medicine.
What is the current FDA status of bepridil hydrochloride?
Bepridil hydrochloride is not an actively marketed U.S. product. The former U.S. brand was Vascor, approved for chronic stable angina. The product was discontinued in the United States in the late 1990s, and bepridil is not a current mainstream option in U.S. cardiology practice [1, 3].
U.S. regulatory timeline
| Event |
Approximate timing |
Commercial significance |
| FDA approval of Vascor |
1990 |
Established U.S. branded market for chronic stable angina |
| U.S. commercial use |
1990s |
Limited by safety monitoring and competition |
| U.S. product discontinuation |
1997 |
Removed the principal Western commercial market |
| Current U.S. position |
No active mainstream marketed product |
No material U.S. revenue platform |
The FDA labeling identified serious ventricular arrhythmia and QT-prolongation risks. The product was not positioned as a first-line treatment for broad hypertension or routine rate control [1].
A discontinued U.S. drug should not automatically be interpreted as having a formal FDA safety withdrawal. The commercial result, however, was the same: U.S. branded sales ended and the product lost relevance in the largest pharmaceutical market.
What is the international market for bepridil hydrochloride?
Japan is the principal identifiable continuing market. Bepridil hydrochloride hydrate has been marketed in Japan in tablet formulations, including 50 mg and 100 mg strengths, for angina and atrial fibrillation or flutter indications [2].
Geographic market profile
| Market |
Status |
Commercial assessment |
| United States |
No mainstream marketed product |
Commercial market effectively inactive |
| Japan |
Established niche use |
Principal continuing market |
| Europe |
No major current branded market identified |
Low or negligible commercial contribution |
| China and other Asian markets |
Local availability may exist in selected settings |
Fragmented, difficult to quantify |
| Global market |
Mature and small |
Generic or legacy-product economics |
Japan's market is supported by physician familiarity, approved arrhythmia use, and treatment patterns that differ from U.S. and European practice. The market remains constrained by the drug's proarrhythmic profile and by the availability of amiodarone, sotalol, catheter ablation, and other rhythm-management approaches.
How large is the bepridil hydrochloride market?
The global market is small, and public company filings generally do not report bepridil hydrochloride as a separate revenue category. The product is usually included within broader generic, hospital, or cardiovascular portfolios.
Revenue exposure
Bepridil hydrochloride has the following financial characteristics:
- No publicly identified blockbuster brand.
- No meaningful U.S. revenue base.
- Limited pricing power because of generic competition.
- Low promotional spending relative to newer cardiovascular therapies.
- Revenue concentration in a small number of geographic markets and suppliers.
- Limited upside from indication expansion because of cardiac safety concerns.
For manufacturers, bepridil is more likely to contribute incremental portfolio revenue than strategic growth. Its financial value may come from maintaining a hospital or cardiovascular product line, securing supply contracts, or serving a stable niche population.
A defensible standalone global sales estimate cannot be derived from public FDA, PMDA, or company disclosures. The absence of reported product-level revenue is itself relevant: bepridil hydrochloride is not a material disclosed growth driver for major multinational pharmaceutical companies.
When did bepridil hydrochloride lose exclusivity?
Bepridil hydrochloride lost meaningful commercial exclusivity decades ago. The active pharmaceutical ingredient and core clinical concept date to the pre-generic era, and the relevant original compound and product patents would have expired before the current market period.
There is no evidence of a current composition-of-matter patent protecting bepridil hydrochloride in major markets. Any remaining intellectual-property value would more likely relate to:
- A specific formulation;
- A manufacturing process;
- A salt or hydrate form;
- A polymorph;
- A packaging or device configuration;
- A jurisdiction-specific use claim.
Those rights would need to be assessed individually through national patent registers. They do not create a material global exclusivity position for the base drug.
What patents protect bepridil hydrochloride?
No active global patent estate of commercial significance is publicly associated with bepridil hydrochloride as a mature marketed molecule. The primary patent barrier has expired, and the product is not known for a current Orange Book patent strategy.
Orange Book status
The former U.S. Vascor product is not a current U.S. commercial reference product with a meaningful Orange Book lifecycle-management position. No active U.S. branded market is available to support a conventional Paragraph IV defense strategy.
| IP category |
Current relevance |
| Original molecule patent |
Expired |
| Original U.S. product protection |
Expired or commercially inactive |
| Current Orange Book strategy |
No material active position identified |
| Formulation patents |
Potentially jurisdiction-specific, but no major commercial barrier identified |
| Method-of-use patents |
No widely recognized active global exclusivity platform |
| Manufacturing patents |
Possible process-level rights; unlikely to block broad generic entry |
Are there Paragraph IV challenges to bepridil hydrochloride?
No significant current U.S. Paragraph IV litigation involving bepridil hydrochloride is publicly identified. The reason is commercial rather than legal: the branded U.S. reference product is no longer a meaningful active market, so a generic applicant has little incentive to challenge a high-value innovator franchise.
Paragraph IV litigation is most valuable when:
- The reference product has substantial sales;
- The innovator has enforceable listed patents;
- A generic launch can capture a large market;
- The generic applicant can obtain a 180-day exclusivity advantage.
Bepridil does not currently satisfy that profile in the United States.
What formulation patents protect bepridil hydrochloride?
The principal commercial formulations are conventional oral tablets. There is no widely recognized long-acting injectable, transdermal, implantable, or complex modified-release platform associated with bepridil hydrochloride.
This limits lifecycle-management opportunities. Conventional tablets are easier to replicate, and formulation differentiation has little value when:
- The active ingredient is old;
- The market is small;
- The clinical indication is narrow;
- Safety monitoring restricts broad uptake;
- Physicians have established alternatives.
A formulation patent could still be relevant for a specific manufacturer in a specific country, but it would not be expected to support durable global pricing power.
What patent litigation affects bepridil hydrochloride?
No major ongoing patent litigation is publicly associated with bepridil hydrochloride. The product's central commercial issues are regulatory status, clinical safety, supply continuity, and prescribing demand rather than infringement disputes.
The litigation profile contrasts with newer cardiovascular drugs, where patent disputes can involve composition patents, crystalline forms, combination products, dosing regimens, and method-of-treatment claims. Bepridil's litigation exposure is low because its commercially important patents are old and its U.S. market is inactive.
How does bepridil compare with competing antiarrhythmic drugs?
Bepridil competes clinically with drugs that have stronger commercial infrastructure or broader current use.
| Drug |
Main commercial position |
Comparison with bepridil |
| Amiodarone |
Broad rhythm-control use; generic |
More established globally but has substantial long-term toxicity |
| Sotalol |
Generic antiarrhythmic and beta-blocking activity |
Competes in atrial and ventricular arrhythmias; requires QT monitoring |
| Dronedarone |
Branded rhythm-control product in selected patients |
More modern commercial positioning but narrower safety and efficacy tradeoffs |
| Ranolazine |
Chronic angina therapy |
Competes more directly in antianginal treatment, with different electrophysiology |
| Catheter ablation |
Procedural treatment for atrial fibrillation |
Reduces long-term dependence on antiarrhythmic drugs in selected patients |
| Bepridil |
Niche legacy therapy, especially in Japan |
Limited by QT prolongation and small geographic market |
Bepridil can be clinically useful where physicians seek rhythm control and other options are unsuitable. Its commercial disadvantage is that its safety-management burden is high without a corresponding patent or pricing advantage.
What is the biosimilar risk for bepridil hydrochloride?
Biosimilar risk is zero in the conventional regulatory sense because bepridil hydrochloride is a chemically synthesized small molecule, not a biologic. The relevant competitive threat is generic substitution.
Generic competition is structurally strong because the product is an oral small molecule with an old active ingredient. Any remaining market is vulnerable to:
- Multiple-source generic entry;
- Tender-based price reductions;
- Hospital procurement pressure;
- Substitution among approved tablet strengths;
- Supplier consolidation and discontinuation.
The principal risk is therefore margin erosion, not biosimilar displacement.
Are there licensing deals for bepridil hydrochloride?
No major recent licensing transaction involving bepridil hydrochloride is publicly identifiable. The molecule is too mature and commercially limited to attract the type of regional or global licensing activity seen with novel antiarrhythmic drugs.
Potential transactions would more likely involve:
- A local marketing authorization;
- A generic supply agreement;
- A Japanese distribution arrangement;
- A portfolio acquisition involving multiple mature products;
- Contract manufacturing or API supply.
Such agreements generally have limited disclosure and would not indicate a revaluation of bepridil's global commercial potential.
What manufacturing and supply risks affect bepridil hydrochloride?
Manufacturing risk is more relevant than patent risk. A mature niche drug may have few active API suppliers and limited finished-dose capacity. Low volumes can make production economically unattractive, creating discontinuation or shortage risk even when demand remains stable.
Key supply-chain factors include:
- Availability of bepridil hydrochloride or its hydrate form;
- Validation of tablet manufacturing processes;
- Stability and impurity controls;
- Regulatory qualification of alternate suppliers;
- Minimum batch economics;
- Dependence on a small number of Japanese or regional manufacturers.
For a generic manufacturer, supply reliability can be a competitive advantage. For purchasers, the main risk is not excessive patent pricing but loss of a qualified supplier.
What is the financial trajectory for bepridil hydrochloride?
The financial trajectory is mature-to-declining, with localized stability rather than growth.
Commercial phases
| Period |
Financial trajectory |
Principal driver |
| Initial launch period |
Growth from branded entry |
New antianginal product and physician adoption |
| 1990s U.S. period |
Limited commercial expansion |
Safety restrictions and competitive pressure |
| Post-U.S. discontinuation |
Sharp reduction in global value |
Loss of U.S. branded market |
| Generic and regional period |
Low-margin stabilization |
Japanese and selected local demand |
| Current outlook |
Flat to declining |
Aging product, substitution, supply concentration |
A reasonable investment view is:
- Revenue scale: low.
- Growth rate: negative to flat.
- Gross margin: potentially acceptable for efficient generic suppliers, but not structurally high.
- Pricing power: weak.
- Regulatory upside: limited.
- Litigation upside: negligible.
- Supply-chain value: potentially more important than patent value.
- Strategic value: portfolio maintenance, not platform expansion.
What generic launch scenarios exist for bepridil hydrochloride?
In the United States, a conventional generic launch scenario has low commercial relevance because the branded market is inactive. In Japan or other continuing markets, generic entry can produce three outcomes:
Stable niche market
A small number of suppliers maintain the product, preserving availability and moderate price competition. This is the most likely scenario where physician demand remains consistent.
Price erosion and supplier exit
Additional generic entrants reduce prices, causing some manufacturers to withdraw. Supply becomes concentrated among fewer suppliers.
Demand decline and discontinuation
Physicians increasingly shift to ablation, amiodarone, sotalol, or newer management approaches. Volumes fall below efficient manufacturing levels, leading to product discontinuation.
A major branded relaunch is unlikely without a new clinical positioning, a differentiated formulation, or a substantial change in treatment guidelines. The available evidence does not indicate such a platform.
How strong is the patent estate for bepridil hydrochloride?
The patent estate is weak from a current commercial perspective. The original molecule is old, no major active U.S. Orange Book strategy is apparent, and the product has no meaningful biologic or device-based protection.
Patent strength should be scored as follows:
| Attribute |
Assessment |
| Composition-of-matter protection |
Expired |
| Market exclusivity |
None of material current value |
| Formulation differentiation |
Limited |
| Method-of-use protection |
Limited or jurisdiction-specific |
| Generic blocking power |
Low |
| Litigation leverage |
Low |
| Manufacturing know-how value |
Moderate for supply continuity |
| Overall patent strength |
Weak |
Key Takeaways
- Bepridil hydrochloride is a mature, low-revenue cardiovascular drug with no material U.S. commercial franchise.
- Japan is the principal continuing market identified in public regulatory materials.
- The drug is used for angina and selected atrial arrhythmias but is constrained by QT prolongation and torsades de pointes risk.
- Core patent protection expired decades ago.
- No major current Orange Book, Paragraph IV, biosimilar, licensing, or patent-litigation story is associated with the product.
- Generic competition is the relevant commercial force.
- Financial performance is likely flat to declining, with revenue concentrated in niche regional markets.
- Supply continuity and manufacturer participation are more important than patent barriers.
- The product has portfolio value for selected generic or regional manufacturers, but limited strategic value for multinational pharmaceutical companies.
FAQs About Bepridil Hydrochloride
Is bepridil hydrochloride still sold in the United States?
No mainstream U.S. marketed product is currently identified. The former Vascor product was discontinued after its 1990s commercial period.
Is bepridil hydrochloride a generic drug?
Yes. It is an old chemically synthesized small molecule with expired primary exclusivity. The current competitive model is generic supply rather than branded innovation.
Does bepridil hydrochloride have biosimilar competition?
No. Biosimilars apply to biologic medicines. Bepridil faces generic, not biosimilar, competition.
Why is bepridil hydrochloride still used in Japan?
Japan has maintained clinical use for selected angina and atrial fibrillation or flutter patients. Local treatment practice, regulatory labeling, and physician experience support a niche market despite safety constraints.
Could bepridil hydrochloride return as a profitable U.S. product?
A conventional relaunch would face limited demand, strong generic economics, established alternatives, and substantial cardiac safety-management requirements. Without a differentiated formulation or new evidence-based indication, the commercial opportunity is limited.
References
-
U.S. Food and Drug Administration. (1990). Vascor (bepridil hydrochloride) prescribing information. FDA.
-
Pharmaceuticals and Medical Devices Agency. (n.d.). Bepricor tablets 50 mg and 100 mg: Japanese product information and interview form. PMDA.
-
U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
